Skip to main content
NASDAQ:LBPH

Longboard Pharmaceuticals Competitors

$8.58
-0.18 (-2.05 %)
(As of 05/14/2021 09:52 AM ET)
Add
Compare
Today's Range
$8.58
$8.75
50-Day Range
$8.52
$17.30
52-Week Range
$8.12
$18.95
Volume200 shs
Average Volume36,869 shs
Market Capitalization$145.15 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Longboard Pharmaceuticals (NASDAQ:LBPH) Vs. FNCH, IVA, VACC, ACHL, MIGI, and BMEA

Should you be buying LBPH stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Longboard Pharmaceuticals, including Finch Therapeutics Group (FNCH), Inventiva (IVA), Vaccitech (VACC), Achilles Therapeutics (ACHL), Mawson Infrastructure Group (MIGI), and Biomea Fusion (BMEA).

Finch Therapeutics Group (NASDAQ:FNCH) and Longboard Pharmaceuticals (NASDAQ:LBPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Finch Therapeutics Group and Longboard Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Finch Therapeutics Group00303.00
Longboard Pharmaceuticals00503.00

Finch Therapeutics Group currently has a consensus target price of $29.3333, suggesting a potential upside of 142.62%. Longboard Pharmaceuticals has a consensus target price of $32.75, suggesting a potential upside of 281.70%. Given Longboard Pharmaceuticals' higher possible upside, analysts plainly believe Longboard Pharmaceuticals is more favorable than Finch Therapeutics Group.

Profitability

This table compares Finch Therapeutics Group and Longboard Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Finch Therapeutics GroupN/AN/AN/A
Longboard PharmaceuticalsN/AN/AN/A

Earnings & Valuation

This table compares Finch Therapeutics Group and Longboard Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Finch Therapeutics GroupN/AN/AN/AN/AN/A
Longboard PharmaceuticalsN/AN/AN/AN/AN/A

Summary

Longboard Pharmaceuticals beats Finch Therapeutics Group on 2 of the 2 factors compared between the two stocks.

Inventiva (NYSE:IVA) and Longboard Pharmaceuticals (NASDAQ:LBPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.

Earnings & Valuation

This table compares Inventiva and Longboard Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InventivaN/AN/AN/AN/AN/A
Longboard PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for Inventiva and Longboard Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inventiva10402.60
Longboard Pharmaceuticals00503.00

Inventiva currently has a consensus target price of $27.3333, suggesting a potential upside of 93.17%. Longboard Pharmaceuticals has a consensus target price of $32.75, suggesting a potential upside of 281.70%. Given Longboard Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Longboard Pharmaceuticals is more favorable than Inventiva.

Profitability

This table compares Inventiva and Longboard Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InventivaN/AN/AN/A
Longboard PharmaceuticalsN/AN/AN/A

Summary

Longboard Pharmaceuticals beats Inventiva on 3 of the 3 factors compared between the two stocks.

Longboard Pharmaceuticals (NASDAQ:LBPH) and Vaccitech (NASDAQ:VACC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, earnings, dividends and risk.

Profitability

This table compares Longboard Pharmaceuticals and Vaccitech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Longboard PharmaceuticalsN/AN/AN/A
VaccitechN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings for Longboard Pharmaceuticals and Vaccitech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Longboard Pharmaceuticals00503.00
Vaccitech0000N/A

Longboard Pharmaceuticals currently has a consensus price target of $32.75, suggesting a potential upside of 281.70%. Given Longboard Pharmaceuticals' higher probable upside, equities research analysts clearly believe Longboard Pharmaceuticals is more favorable than Vaccitech.

Earnings & Valuation

This table compares Longboard Pharmaceuticals and Vaccitech's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Longboard PharmaceuticalsN/AN/AN/AN/AN/A
VaccitechN/AN/AN/AN/AN/A

Summary

Longboard Pharmaceuticals beats Vaccitech on 2 of the 2 factors compared between the two stocks.

Achilles Therapeutics (NASDAQ:ACHL) and Longboard Pharmaceuticals (NASDAQ:LBPH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, earnings, risk and dividends.

Analyst Recommendations

This is a summary of current ratings and target prices for Achilles Therapeutics and Longboard Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Achilles Therapeutics10402.60
Longboard Pharmaceuticals00503.00

Achilles Therapeutics presently has a consensus target price of $21.20, suggesting a potential upside of 55.31%. Longboard Pharmaceuticals has a consensus target price of $32.75, suggesting a potential upside of 281.70%. Given Longboard Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Longboard Pharmaceuticals is more favorable than Achilles Therapeutics.

Valuation and Earnings

This table compares Achilles Therapeutics and Longboard Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Achilles TherapeuticsN/AN/AN/AN/AN/A
Longboard PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Achilles Therapeutics and Longboard Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Achilles TherapeuticsN/AN/AN/A
Longboard PharmaceuticalsN/AN/AN/A

Summary

Longboard Pharmaceuticals beats Achilles Therapeutics on 3 of the 3 factors compared between the two stocks.

Longboard Pharmaceuticals (NASDAQ:LBPH) and Mawson Infrastructure Group (NASDAQ:MIGI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Longboard Pharmaceuticals and Mawson Infrastructure Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Longboard Pharmaceuticals00503.00
Mawson Infrastructure Group0000N/A

Longboard Pharmaceuticals currently has a consensus price target of $32.75, suggesting a potential upside of 281.70%. Given Longboard Pharmaceuticals' higher probable upside, analysts clearly believe Longboard Pharmaceuticals is more favorable than Mawson Infrastructure Group.

Valuation & Earnings

This table compares Longboard Pharmaceuticals and Mawson Infrastructure Group's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Longboard PharmaceuticalsN/AN/AN/AN/AN/A
Mawson Infrastructure GroupN/AN/AN/AN/AN/A

Profitability

This table compares Longboard Pharmaceuticals and Mawson Infrastructure Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Longboard PharmaceuticalsN/AN/AN/A
Mawson Infrastructure GroupN/AN/AN/A

Summary

Longboard Pharmaceuticals beats Mawson Infrastructure Group on 2 of the 2 factors compared between the two stocks.

Longboard Pharmaceuticals (NASDAQ:LBPH) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Profitability

This table compares Longboard Pharmaceuticals and Biomea Fusion's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Longboard PharmaceuticalsN/AN/AN/A
Biomea FusionN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Longboard Pharmaceuticals and Biomea Fusion, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Longboard Pharmaceuticals00503.00
Biomea Fusion00303.00

Longboard Pharmaceuticals currently has a consensus price target of $32.75, suggesting a potential upside of 281.70%. Biomea Fusion has a consensus price target of $26.3333, suggesting a potential upside of 54.90%. Given Longboard Pharmaceuticals' higher probable upside, analysts clearly believe Longboard Pharmaceuticals is more favorable than Biomea Fusion.

Valuation & Earnings

This table compares Longboard Pharmaceuticals and Biomea Fusion's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Longboard PharmaceuticalsN/AN/AN/AN/AN/A
Biomea FusionN/AN/AN/AN/AN/A

Summary

Longboard Pharmaceuticals beats Biomea Fusion on 2 of the 2 factors compared between the two stocks.


Longboard Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
FNCH
Finch Therapeutics Group
2.0$12.09-0.5%$567.15 millionN/A0.00
Inventiva logo
IVA
Inventiva
1.4$14.15-1.1%$546.61 millionN/A0.00
VACC
Vaccitech
0.3$17.41-9.5%$536.51 millionN/A0.00Gap Up
ACHL
Achilles Therapeutics
1.6$13.65-7.6%$512.24 millionN/A0.00Earnings Announcement
Quiet Period Expiration
Analyst Revision
Gap Up
MIGI
Mawson Infrastructure Group
0.0$0.89-6.7%$471.73 millionN/A0.00Upcoming Earnings
BMEA
Biomea Fusion
1.7$17.00-6.4%$457.70 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Up
VECT
VectivBio
1.6$12.79-0.8%$431.65 millionN/A0.00Quiet Period Expiration
SGTX
Sigilon Therapeutics
1.4$13.25-6.0%$417.77 millionN/A0.00Earnings Announcement
Analyst Revision
News Coverage
Angion Biomedica logo
ANGN
Angion Biomedica
1.6$14.48-3.3%$412.78 millionN/A0.00Gap Down
Landos Biopharma logo
LABP
Landos Biopharma
1.5$10.30-1.0%$409.20 millionN/A0.00Gap Up
RAIN
Rain Therapeutics
1.3$14.95-0.9%$391.61 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$17.15-7.7%$390.30 millionN/A0.00Gap Down
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
1.7$15.78-3.9%$380.90 millionN/A0.00
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$9.42-8.5%$370.65 millionN/A0.00News Coverage
Gap Up
PRTG
Portage Biotech
0.0$28.25-0.7%$338.81 millionN/A0.00
HOWL
Werewolf Therapeutics
0.3$11.65-0.4%$319.45 millionN/A0.00Gap Up
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$9.66-5.6%$312.00 millionN/A0.00Earnings Announcement
Analyst Revision
News Coverage
IMPL
Impel NeuroPharma
0.3$13.84-0.8%$270.84 millionN/A0.00
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.5$6.35-8.3%$247.46 millionN/A-2.51
Unity Biotechnology logo
UBX
Unity Biotechnology
1.3$4.28-0.5%$233.40 millionN/A-2.28Earnings Announcement
VINC
Vincerx Pharma
1.0$16.34-1.0%$228.50 millionN/A0.00
RPHM
Reneo Pharmaceuticals
2.0$8.10-1.1%$193.93 millionN/A0.00Quiet Period Expiration
Gap Up
Annovis Bio logo
ANVS
Annovis Bio
1.7$24.23-3.9%$161.73 millionN/A0.00Upcoming Earnings
Analyst Report
News Coverage
Gap Up
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.1$7.09-9.9%$159.12 millionN/A0.00Earnings Announcement
Analyst Downgrade
News Coverage
Gap Up
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$7.87-4.7%$143.77 millionN/A0.00Gap Up
GANX
Gain Therapeutics
1.7$9.37-3.9%$106.89 millionN/A0.00Gap Up
EVAX
Evaxion Biotech A/S
1.7$5.30-5.7%$101.76 millionN/A0.00News Coverage
Gap Up
Trading Halted
LGVN
Longeveron
0.0$5.20-1.9%$98.58 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$17.52-3.8%$68.47 millionN/A0.00News Coverage
Gap Up
UPC
Universe Pharmaceuticals
0.0$3.15-1.9%$67.21 millionN/A0.00Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
1.0$4.60-6.5%$49.29 millionN/A0.00Gap Down
CUBT
Curative Biotechnology
0.0$0.11-8.7%$44.64 millionN/A0.00Gap Up
Viracta Therapeutics logo
VIRX
Viracta Therapeutics
1.5$7.66-0.0%$39.63 millionN/A0.00Analyst Downgrade
Gap Up
VIRI
Virios Therapeutics
1.3$4.71-2.1%$39.23 millionN/A0.00News Coverage
CMMB
Chemomab Therapeutics
1.7$17.77-6.6%$38.77 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Up
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.32-3.6%$37.69 millionN/A0.00Gap Up
VYNT
Vyant Bio
0.0$3.16-8.9%$31.70 millionN/A0.00Upcoming Earnings
News Coverage
MYMD
MyMD Pharmaceuticals
0.0$3.68-1.1%$30.31 millionN/A0.00Upcoming Earnings
VLON
Vallon Pharmaceuticals
0.0$3.71-1.1%$25.27 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3$3.85-2.6%$19.04 millionN/A0.00Gap Down
BCTX
BriaCell Therapeutics
0.0$3.18-3.1%$17.91 millionN/A0.00Gap Up
PALI
Palisade Bio
0.0$3.88-18.6%$13.26 millionN/A0.00Upcoming Earnings
Gap Down
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.32-0.4%$0.00N/A0.00Earnings Announcement
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.06-0.0%$0.00N/A0.00Gap Down
SCPS
Scopus BioPharma
1.4$5.30-2.5%$0.00N/A0.00
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.